Medico Intercontinental Ltd
F&OMILBSE
₹24.70▼ -0.41 (-1.63%)
Whole company worth₹25 Cr
Price for ₹1 of profit₹37
1-year range₹21 – ₹43
The short version
A shrinking, loss-making business.
What Medico Intercontinental does
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs).
Worked out from Medico Intercontinental's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Medico Intercontinental is a micro-sized company in pharmaceuticals & biotechnology.
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
- Whole company is worth
- ₹25 crore
- Run by
- Dilipkumar Bhogilal Shah
- Employees
- 43,000
- Shareholders
- 3,446 people
- Listed since
- 2016
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have shrunk 70% a year for 5 years.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
For every ₹100 it sells, it spends ₹113.
Here is where the money from Medico Intercontinental's sales went in FY26, the latest full year it has reported.
₹75
₹20
₹9.7
₹100 of sales ends here
- ₹75Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹20Running the businessstaff, rent, marketing, power and everything else
- ₹9.7Interest on its loansthe cost of borrowed money
- ₹6.5Wear and tearmachines, stores and buildings losing value over time
- ₹2.1Taxincome tax paid to the government
- ₹13Lossspent beyond what came in — covered by savings or new money
On the money its owners have put in
It lost ₹7 for every ₹100 its owners have invested.
Bank FD ~₹6–7
₹-7
₹-20₹-10₹0₹10₹20₹30₹40
Return on equity (ROE) measures the yearly profit made on the money shareholders have put into the business. Negative means the business is eating into that money.
04Is the price high or low?
You pay ₹37 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 37 means buyers are paying for about 37 years of today's profit up front.
The share price over the past year
It is 43% below its highest price of the past year and 20% above its lowest.
05Who owns it?
Its founders and parent group own 59 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 3,446 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
The figures raise more questions than they answer.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
Nothing stands out in its favour in the figures we have.
Worth watching
- Sales fell 12% in the latest financial year.
- Sales have been shrinking — 70% a year.
- Lost ₹11 crore in its last financial year.
- Carries meaningful debt — ₹143 of loans for every ₹100 of shareholders' money.
- Thinly traded — only about ₹1 lakh of shares change hands a day, so buying or selling can move the price.
07What happened lately?
Latest quarter: sales down 3%, a loss.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹21 Cr
▼ 3.0% on a year earlier
Loss
₹4.0 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Medico Intercontinental?
This page describes Medico Intercontinental using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Medico Intercontinental Ltd (MIL): company summary
The company's business is deteriorating, with annual revenue falling 12.4% to ₹84 crore and annual net profit swinging to a loss of ₹11 crore from a profit of ₹5 crore.
Medico Intercontinental Ltd (MIL) is a micro-cap Healthcare company valued at ₹25 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.
- Recent price move
- Medico Intercontinental Ltd last traded at ₹24.7, modestly down 1.63% on the day.
- Recent developments
- On 2026-09-30, the company reported a net loss of ₹11 crore for its latest financial year, marking a significant shift from the prior year's profit. The latest quarter ended on 2026-06-30, with a loss of ₹4 crore compared to a loss of ₹2 crore in the same quarter a year earlier.
- Financial performance
- The company's business is deteriorating, with annual revenue falling 12.4% to ₹84 crore and annual net profit swinging to a loss of ₹11 crore from a profit of ₹5 crore. The latest quarter shows a loss widening from ₹2 crore to ₹4 crore despite revenue remaining flat at ₹21 crore.
- Valuation multiples
- The stock trades at 36.9 times earnings, a premium to the Healthcare median of 32.0, 5.35 times book value. It yields 0.9%.
- Things to watch
- The company is currently in a net loss, with a net profit margin of -13.1% and return on equity of -6.8%. Revenue has declined sharply over the past three years, with a compound annual growth rate of -87.6%, and the company's debt to equity ratio stands at 1.43, indicating leverage.
- Where it stands
- The company is reporting a net loss of ₹11 crore for the latest financial year, with a loss widening in the latest quarter to ₹4 crore. The most significant movement is the net loss, which has grown from a profit of ₹5 crore a year earlier.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals & Biotechnology
Explore Medico Intercontinental Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Medico Intercontinental Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Medico Intercontinental Ltd with peers
Medico Intercontinental Ltd vs Sun Pharmaceutical Industries LimitedMedico Intercontinental Ltd vs Divi's Laboratories LimitedMedico Intercontinental Ltd vs Torrent Pharmaceuticals LimitedMedico Intercontinental Ltd vs Laurus Labs LimitedMedico Intercontinental Ltd vs Zydus Lifesciences LimitedMedico Intercontinental Ltd vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Medico Intercontinental Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing